The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Bretuximab vedotin plus re-induction chemotherapy for CD30+ R/R AML
Bretuximab vedotin plus re-induction chemotherapy is under investigation for the treatment of CD30+ relapsed/refractory acute myeloid leukemia (AML). Amir Fathi, MD, MPH, of the Massachusetts General Hospital, Boston, MA, discusses the results of this Phase I study (NCT01830777), highlighting tolerability, safety and response data. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
